Expansion of Protein Interaction Maps by Phage Peptide Display Using MDM2 as a Prototypical Conformationally Flexible Target Protein

Journal of Molecular Biology

Volumn 337, Issue 1, 2004, Pages 129-145

  Burch, Lindsay ^a   Shimizu, Harumi ^a,c   Smith, Amanda ^a   Patterson, Cam ^b   Hupp, Ted R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

Author keywords

Chaperone; HSP90; MDM2; p53; Phage peptide display

Indexed keywords

HEAT SHOCK PROTEIN 90; PROTEIN MDM2; REGULATOR PROTEIN;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA BINDING; ENVIRONMENTAL TEMPERATURE; HUMAN; HUMAN CELL; PHAGE PEPTIDE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; TECHNIQUE; ZINC FINGER MOTIF;

EID: 1442277689     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.01.017     Document Type: Article

References (56)

1. Ashcroft M., Taya Y., Vousden K.H. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:2000;3224-3233.
2. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
3. Lane D.P., Hupp T.R. Drug discovery and p53. Drug Discov. Today. 8:2003;347-355.
4. Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., et al. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281:1998;1674-1677.
5. Shieh S.Y., Ahn J., Tamai K., Taya Y., Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev. 14:2000;289-300.
6. Dornan D., Hupp T.R. Inhibition of p53-dependent transcription by BOX-I phospho-peptide mimetics that bind to p300. EMBO Rep. 2:2001;139-144.
7. Dornan D., Shimizu H., Perkins N.D., Hupp T.R. DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem. 278:2003;13431-13441.
8. Barlev N.A., Liu L., Chehab N.H., Mansfield K., Harris K.G., Halazonetis T.D., Berger S.L. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell. 8:2001;1243-1254.
9. Thut C.J., Goodrich J.A., Tjian R. Repression of p53-mediated transcription by MDM2: a dual mechanism. Genes Dev. 11:1997;1974-1986.
10. Freedman D.A., Levine A.J. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol. Cell. Biol. 18:1998;7288-7293.
11. Boddy M.N., Freemont P.S., Borden K.L. The p53-associated protein MDM2 contains a newly characterized zinc-binding domain called the RING finger. Trends Biochem. Sci. 19:1994;198-199.
12. Lai Z., Ferry K.V., Diamond M.A., Wee K.E., Kim Y.B., Ma J., et al. Human mdm2 mediates multiple mono-ubiquitination of p53 by a mechanism requiring enzyme isomerization. J. Biol. Chem. 276:2001;31357-31367.
13. Lai Z., Freedman D.A., Levine A.J., McLendon G.L. Metal and RNA binding properties of the hdm2 RING finger domain. Biochemistry. 37:1998;17005-17015.
14. Elenbaas B., Dobbelstein M., Roth J., Shenk T., Levine A.J. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:1996;439-451.
15. Burch L.R., Midgley C.A., Currie R.A., Lane D.P., Hupp T.R. Mdm2 binding to a conformationally sensitive domain on p53 can be modulated by RNA. FEBS Letters. 472:2000;93-98.
16. Meulmeester E., Frenk R., Stad R., de Graaf P., Marine J.C., Vousden K.H., Jochemsen A.G. Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol. Cell. Biol. 23:2003;4929-4938.
17. Shimizu H., Hupp T.R. Intrasteric regulation of MDM2. Trends Biochem. Sci. 28:2003;346-349.
18. Buerger C., Groner B. Bifunctional recombinant proteins in cancer therapy: cell penetrating peptide aptamers as inhibitors of growth factor signaling. J. Cancer Res. Clin. Oncol. 129:2003;669-675.
19. Boulton S.J., Gartner A., Reboul J., Vaglio P., Dyson N., Hill D.E., Vidal M. Combined functional genomic maps of the C. elegans DNA damage response. Science. 295:2002;127-131.
20. Seeliger M.A., Breward S.E., Friedler A., Schon O., Itzhaki L.S. Cooperative organization in a macromolecular complex. Nature Struct. Biol. 10:2003;718-724.
21. Kamal A., Thao L., Sensintaffar J., Zhang L., Boehm M.F., Fritz L.C., Burrows F.J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature. 425:2003;407-410.
22. Romanov V.I. Phage display selection and evaluation of cancer drug targets. Curr. Cancer Drug Targets. 3:2003;119-129.
23. Schon O., Friedler A., Bycroft M., Freund S.M., Fersht A.R. Molecular mechanism of the interaction between MDM2 and p53. J. Mol. Biol. 323:2002;491-501.
24. Shimizu H., Burch L.R., Smith A.J., Dornan D., Wallace M., Ball K.L., Hupp T.R. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J. Biol. Chem. 277:2002;28446-28458.
25. Dornan D., Shimizu H., Burch L., Smith A., Hupp T. proline-repeat domain of p53 binds directly to the transcription coactivator p300 and allosterically mediates DNA-dependent acetylation. Mol. Cell. Biol. 23:2003;8846-8861.
26. Kussie P.H., Gorina S., Marechal V., Elenbaas B., Moreau J., Levine A.J., Pavletich N.P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 274:1996;948-953.
27. Blagosklonny M.V., Toretsky J., Bohen S., Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl Acad. Sci. USA. 93:1996;8379-8383.
28. Peng Y., Chen L., Li C., Lu W., Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J. Biol. Chem. 276:2001;40583-40590.
29. Gannon J.V., Greaves R., Iggo R., Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1990;1595-1602.
30. Blaydes J.P., Craig A.L., Wallace M., Ball H.M., Traynor N.J., Gibbs N.K., Hupp T.R. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene. 19:2000;3829-3839.
31. Hansen S., Hupp T.R., Lane D.P. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC cell transformation group. J. Biol. Chem. 271:1996;3917-3924.
32. Milner J., Medcalf E.A. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell. 65:1991;765-774.
33. Foster B.A., Coffey H.A., Morin M.J., Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science. 286:1999;2507-2510.
34. Whitesell L., Sutphin P., An W.G., Schulte T., Blagosklonny M.V., Neckers L. Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo. Oncogene. 14:1997;2809-2816.
35. Connell P., Ballinger C.A., Jiang J., Wu Y., Thompson L.J., Hohfeld J., Patterson C. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nature Cell. Biol. 3:2001;93-96.
36. Cyr D.M., Hohfeld J., Patterson C. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem. Sci. 27:2002;368-375.
37. Momand J., Zambetti G.P. Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics. Oncogene. 12:1996;2279-2289.
38. Sepehrnia B., Paz I.B., Dasgupta G., Momand J. Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. J. Biol. Chem. 271:1996;15084-15090.
39. Blaydes J.P., Luciani M.G., Pospisilova S., Ball H.M., Vojtesek B., Hupp T.R. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J. Biol. Chem. 276:2001;4699-4708.
40. Craig A.L., Blaydes J.P., Burch L.R., Thompson A.M., Hupp T.R. Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene. 18:1999;6305-6312.
41. Blaydes J.P., Wynford-Thomas D. The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. Oncogene. 16:1998;3317-3322.
42. Barak Y., Juven T., Haffner R., Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J. 12:1993;461-468.
43. Hall A.R., Milner J. Specific p53-DNA complexes contain an mdm2-related protein. Oncogene. 14:1997;1371-1376.
44. Leveillard T., Wasylyk B. The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. J. Biol. Chem. 272:1997;30651-30661.
45. Lin H.K., Wang L., Hu Y.C., Altuwaijri S., Chang C. Phosphorylation- dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J. 21:2002;4037-4048.
46. Lohrum M.A., Ludwig R.L., Kubbutat M.H., Hanlon M., Vousden K.H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell. 3:2003;577-587.
47. Hallows K.R., Raghuram V., Kemp B.E., Witters L.A., Foskett J.K. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J. Clin. Invest. 105:2000;1711-1721.
48. Cotto J.J., Morimoto R.I. Stress-induced activation of the heat-shock response: cell and molecular biology of heat-shock factors. Biochem. Soc. Symp. 64:1999;105-118.
49. Teter S.A., Klionsky D.J. How to get a folded protein across a membrane. Trends Cell. Biol. 9:1999;428-431.
50. Jaattela M. Escaping cell death: survival proteins in cancer. Expt. Cell. Res. 248:1999;30-43.
51. Hupp T.R., Lane D.P. Allosteric activation of latent p53 tetramers. Curr. Biol. 4:1994;865-875.
52. Hupp T.R., Lane D.P. Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. J. Biol. Chem. 270:1995;18165-18174.
53. Johnson B.D., Chadli A., Felts S.J., Bouhouche I., Catelli M.G., Toft D.O. Hsp90 chaperone activity requires the full-length protein and interaction among its multiple domains. J. Biol. Chem. 275:2000;32499-324507.
54. Craig A.L., Burch L., Vojtesek B., Mikutowska J., Thompson A., Hupp T.R. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342:1999;133-141.
55. Honda R., Tanaka H., Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters. 420:1997;25-27.
56. Delphin C., Baudier J. The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of Ras-transformed embryo fibroblasts growth arrest. J. Biol. Chem. 269:1994;29579-29587.